December 3, 2019 Comments Off on Protalix Biotherapeutics Inc. Securities Investigation Blog, Current Investigations

Protalix Biotherapeutics Inc. Securities Investigation

Protalix Biotherapeutics Inc. Securities Investigation, featured by Top Securities Fraud Attorneys, The White Law Group

Protalix Biotherapeutics Inc. Investment Losses

Have you suffered losses investing in Protalix Biotherapeutics Inc.? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Dispute Resolution claim against the brokerage firm that sold you the investment.

Protalix Biotherapeutics Inc., a biopharmaceutical company, is reportedly focused on the development and commercialization of recombinant therapeutic proteins including a late-stage clinical product expressed through its proprietary plant cell-based expression system.

On August 30, 2019, the company reportedly announced that it received a deficiency letter from NYSE American LLC stating that the Company is not in compliance with the continued listing standards as it has reported a stockholders’ equity deficiency as of June 30, 2019 and net losses in its five most recent fiscal years ended December 31, 2018.

The problem with biopharmaceutical stocks such as Protalix Biotherapeutics Inc. is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy clinical testing trials that yield specific data. If the expected data or end points are not met, the stock can drop drastically.

Without a strong understanding of the company and its basic operations, investors may be looking at serious losses.

Investigating Potential Claims

The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly recommending high-risk biopharma stocks, like Protalix Biotherapeutics Inc. to investors.

Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.

If you have concerns regarding investment losses in Protalix Biotherapeutics Inc., please call the securities attorneys at The White Law Group for a free consultation at 888-637-5510.

The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.

For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit https://www.whitesecuritieslaw.com.

 

 

 

Comments are closed.